Tough on the tumor

Easier on you and your caregivers

Get a head STaRT in the fight against brain tumors

A radiation treatment specifically designed for use inside the brain, GammaTile Therapy gives patients new hope in the fight against brain tumors. It can eliminate the need for traditional repeat radiation treatments and associated hospital or clinic visits, so patients can focus on what matters most—healing.

Your neurosurgeon places GammaTile(s) precisely where and when treatment will help the most—at the tumor site immediately after tumor removal.

Radiation is focused right where it is needed—where the tumor is most likely to recur.

GammaTile is designed to protect healthy tissue, minimizing radiation side effects, including hair loss.[1]

Radiation therapy occurs as you go about your daily life.

Get a head STaRT in the fight against brain tumors. 

Find a GammaTile Therapy Center near you.

GammaTile Therapy: Clinical Outcomes

For patients with recurrent meningiomas and recurrent brain metastases, the use of GammaTile Therapy demonstrated a significant delay in treatment site recurrence compared to their previous treatments.[2,3]

Improved local tumor control in patients with recurrent meningiomas and recurrent brain metastases

MENINGIOMA PATIENTS RECURRENCE FREE AT 2 YEARS[2]

BRAIN METASTASES PATIENTS RECURRENCE FREE AT 1 YEAR[3]

Potential to extend overall survival

in patients with recurrent glioblastoma (GBM)

GammaTile Therapy demonstrates a potential for improved overall survival when comparing the effectiveness of surgery plus GammaTile Therapy to other treatment modalities across different clinical studies in patients with recurrent high-grade gliomas.[4,5]

RECURRENT GBM PATIENTS MEDIAN OVERALL SURVIVAL[4,5]

Learn about the company that developed GammaTile Therapy.

REFERENCES

  1. Brachman D, Youssef E, Dardis C, Smith K, Pinnaduwage D, Nakaji P. Surgically targeted radiation therapy: Safety profile of collagen tile brachytherapy in 79 recurrent, previously irradiated intracranial neoplasms on a prospective clinical trial. Brachytherapy. 2019;18(3):S35-S36.

  2. Rogers L, Nakaji P, Youssef E, et al. Resection and surgically targeted radiation therapy for initial salvage treatment of aggressive meningioma: results from a prospective trial. Presented at: CNS 2020 Virtual Conference; September 30, 2020.

  3. Nakaji P, Smith K, Youssef E, et al. Resection and surgically targeted radiation therapy for the treatment of larger recurrent or newly diagnosed brain metastasis: results from a prospective trial. Cureus. 12(11):1-12.

  4. Data on file, GT Medical Technologies, Inc.

  5. Tsien C, Pugh S, Dicker AP, et al. Randomized phase II trial of re-irradiation and concurrent bevacizumab versus bevacizumab alone as treatment for recurrent glioblastoma (NRG Oncology/RTOG 1205): initial outcomes and RT plan quality report. International Journal of Radiation Oncology, Biology, Physics. 2019;105(1):578.

TREATMENT CONSIDERATIONS 

GammaTile Therapy is intended to deliver radiation therapy in patients with newly diagnosed malignant brain tumors and recurrent brain tumors. The potential for, and symptoms of, adverse events related to radiation exposure vary depending on the radiosensitivity of the exposed tissue, the amount of radiation delivered, and the placement of GammaTile(s). Serious side effects related to GammaTile Therapy are rare, and may include radiation brain changes including necrosis. GammaTile Therapy should not be used for patients with known history of hypersensitivity to bovine-derived materials. Possible complications can occur with any neurosurgical procedure, including cerebrospinal fluid leaks, infection, delayed hemorrhage, and adhesion formation.

CONNECT WITH US
  • Twitter
  • LinkedIn
  • Facebook
  • YouTube

©2020 GT Medical Technologies, Inc. I All rights reserved | Privacy Policy | Terms of Use

IMPROVING THE LIVES OF PATIENTS WITH BRAIN TUMORS